Author

K. Saksela

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Organism:mouse· 2 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:protein structure· 1

Frequent Co-Authors

H. Ugurlu· 2 shared L. Levanov· 2 shared O. Vapalahti· 2 shared R. Fagerlund· 2 shared A. Haveri· 1 shared A. Kipar· 1 shared A. Pasternack· 1 shared A. R. Mäkelä· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

H. Ugurlu

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Intranasal inhibitor broadly blocks SARS-CoV-2 including recent highly immunoevasive Omicron subvariants

A. R. Mäkelä, H. Ugurlu, L. Hannula, P. Salminen, R. Kant, R. Fagerlund, S. Mäki, A. Haveri, T. Strandin, L. Kareinen, J. Hepojoki, L. Levanov, A. Pasternack, R. A. Naves, O. Ritvos, , K. Saksela

This paper describes a novel intranasal inhibitor, TriSb92, that effectively neutralizes SARS-CoV-2 and recent Omicron subvariants, offering protection against infection in mice.

bioRxiv · Dec 28, 2021 · PreprintMicrobiology

Evolutionary plasticity of SH3 domain binding by Nef proteins of the HIV 1/SIVcpz lentiviral lineage

Z. Zhao, R. Fagerlund, D. Sauter, H. Tossavainen, P. Permi, F. Kirchhoff, K. Saksela

This paper shows that Nef proteins from HIV and SIV use different structural strategies, called R-clamps, to bind SH3 domains, with variations in amino acids at positions 83 and 120.

bioRxiv · Jun 22, 2021Microbiology

Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro

M. S. Fred, S. Kuivanen, H. Ugurlu, P. Cabrera Casarotto, L. Levanov, K. Saksela, O. Vapalahti, E. Castren

This study tests antidepressants and antipsychotics against SARS-CoV-2 pseudoviruses and finds fluoxetine inhibits infection, including against variants with spike mutations.

bioRxiv · Mar 22, 2021Pharmacology & Toxicology